Indeed, it has been exceptionally interesting to see the emergence of co-activation signatures in prostate cancer that not only focus on one of the classical TFs associated with PCa progression (AR, Myc, p53, and HIF1α) but rather on a combination of an established TF with a biological master regulator or an established TF with another oncogene. The gene discussed is TP53; the disease is prostate carcinoma.